Phase I dose escalation study of lestaurtinib in patients with myelofibrosis

Despite extensive prior clinical investigation in acute leukemia (60 – 100 mg), dose finding studies have not yet established a true maximum tolerated dose (MTD) for the oral multi-kinase inhibitor lestaurtinib in hematologic malignancies. We performed a multicenter, investigator initiated, phase I...

詳細記述

保存先:
書誌詳細
出版年:Leuk Lymphoma
主要な著者: Hexner, Elizabeth O, Mascarenhas J, John, Prchal, Josef, Roboz, Gail J, Baer, Maria R, Ritchie, Ellen K, Leibowitz, David, Demakos, Erin P, Miller, Crystal, Siuty, James, Kleczko, Jill, Price, Leah, Jeschke, Grace, Weinberg, Rona, Basu T, Titiksha, Pahl, Heike L, Orazi, Attilio, Najfeld, Vesna, Marchioli, Roberto, Goldberg, Judith D, Silverman, Lewis R, Hoffman, Ronald
フォーマット: Artigo
言語:Inglês
出版事項: 2015
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5665563/
https://ncbi.nlm.nih.gov/pubmed/25563429
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2014.1001986
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料